Remdesivir: A Possible Treatment for 2019 Novel Coronavirus

Notice: Due to rapidly changing information, the content of this blog post may be obsolete. Please check our article, Some Drugs for COVID-19, and accompanying table, Treatments Considered for COVID-19, which are available free, for updated information. Every day our editors and expert consultants are sifting through the literature, checking government and society updates, and monitoring […]

Truth in TV Advertising: Empagliflozin (Jardiance)

Advertisements for prescription drugs are flooding our TV screens. I don’t think that’s a good thing, but are they untruthful (forbidden) or misleading (more difficult to police)? The long recitals of terrifying side effects add a note of caution, but since they come on so late and are intoned at such high speed, it may […]

Tafamidis (Vyndaqel; Vyndamax): Why Two Products?

Our website now hosts a free article about tafamidis, a new drug in the US approved for treatment of adults with transthyretin-mediated amyloid cardiomyopathy, a progressive, life-threatening, under-diagnosed disease often referred to by its acronym (ATTR-CM). The drug was approved in 2 formulations with different brand names and different doses, both manufactured by Pfizer. Vyndaqel […]

Before Vaccines

The current issue of The Medical Letter includes an article on this year’s influenza vaccine, which reminds me how crazy the world has become. The temperature went up to 108 degrees in Paris, and young women with PhDs are refusing to vaccinate their children, and not just against flu. Well, flu can be scary; the […]

A New Drug for Female Sexual Dysfunction

Ordinarily The Medical Letter does not review new drugs before their price becomes available, but the FDA’s approval of bremelanotide (Vyleesi) for treatment of female sexual dysfunction created so much interest that we felt obliged to break that rule. An article on Vyleesi will appear in our July 29 issue, which is available online now. […]

Gabapentin and Pregabalin for Pain

An interesting recent article in JAMA Internal Medicine was critical of off-label use of gabapentin (Neurontin, and generics) and pregabalin (Lyrica) for treatment of pain,1 a subject The Medical Letter has reviewed with varying degrees of skepticism for many years.2-5 Goodman and Brett point out that both drugs were originally approved as anticonvulsants, but most […]

CBD

It is everywhere, promoted for almost everything. I can hardly walk down the street without having a card pressed into my hand that extols its therapeutic virtues and offers free samples at my neighborhood store. It might be an ingredient in a smoothie or a muffin consumed by an unsuspecting buyer. Mothers feed it to […]